393a470f-8641-493a-98fe-e0ec38c8d7f9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.500
- PROTEIN_SECRETION+0.400
- APOPTOSIS+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- MYC_TARGETS_V1+0.300
- PEROXISOME+0.300
- ANDROGEN_RESPONSE+0.200
- ANGIOGENESIS+0.200
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.300
- MYOGENESIS-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- HYPOXIA-0.200
- PANCREAS_BETA_CELLS-0.200
- SPERMATOGENESIS-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- KRAS_SIGNALING_DN-0.100
- MYC_TARGETS_V2-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6938-01A-11R-1915-07 | — | — | 0.787 |
| 2 | ERR2278855 | — | — | 0.780 |
| 3 | BS_HBJZR69P | Schwannoma | — | 0.775 |
| 4 | BS_XF0ZX2B3 | EPN | Supratentorial EPN | 0.770 |
| 5 | 5C40F9B6-4A54-4861-9DE5-8852BF4B13E7 | — | — | 0.757 |
| 6 | BS_JK0VPG1T | Schwannoma | — | 0.756 |
| 7 | BS_XF0ZX2B3 | Supratentorial Ependymoma | — | 0.754 |
| 8 | BS_M9C4RY4P | Schwannoma | — | 0.752 |
| 9 | BS_H3Y8FWHV | Schwannoma | — | 0.750 |
| 10 | SRR12696798 | — | — | 0.750 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |